Successful Smoking Cessation in COPD: Association with Comorbidities and Mortality

Table 1

Demographics and clinical characteristics of quitters and nonquitters.

Characteristics	All	Quitters^1	Nonquitters	P value
	N = 739 (%)	N = 433 (%)	N = 306 (%)
Men	473 (64)	285 (60.3)	188 (39.7)	NS
Women	266 (36)	148 (55.6)	118 (44.4)
Age, mean (±SD) in years	64.0 (6.8)	65.3 (6.6)	62.3 (6.8)	<0.001
Duration of COPD mean (±SD) in years	5.5 (4.1)	5.8 (4.4)	5.2 (3.8)	NS
BMI (kg/m^2) (±SD)	26.5 (5.3)	26.5 (5.2)	26.5 (5.5)	NS
Pack years (±SD)	41 (23)	43 (24)	38 (22)	0.01
Baseline mean (±SD)
FEV1 % predicted	58.4 (18.9)	56.3 (18.4)	61.3 (19.3)	<0.001
FVC % predicted	73.6 (18.1)	72.6 (17.9)	74.9 (18.3)	0.04
FEV1/FVC %	64.0 (13.9)	62.7 (14.4)	65.8 (13.0)	0.002
After bronchodilatation mean (±SD)
FEV1 % predicted	62.1 (18.3)	60.3 (18.1)	64.4 (18.4)	0.004
FVC % predicted	77.8 (17.3)	77.4 (17.2)	78.4 (17.3)	NS
FEV1/FVC %	64.4 (13.9)	63.0 (14.4)	66.4 (13.0)	0.002
𝑁 (%) of patients with
FEV1 % >80	87 (12.0)	41 (9.6)	46 (15.4)	0.005 for trend
FEV1 % 65–80	191 (26.4)	100 (23.5)	91 (30.5)
FEV1 % 40–64	309 (42.7)	196 (46.1)	113 (37.9)
FEV1% <40	139 (18.8)	88 (20.7)	48 (16.1)
General-health-related QoL score (range 0-1) (±SD)	0.79 (0.11)	0.80 (0.10)	0.78 (0.12)	0.05
Airway specific QoL score; (range 20–0) (±SD)	8.25 (5.03)	7.98 (4.77)	8.63 (5.35)	NS
Comorbidities N (%)
Cardiovascular diseases	216 (29.2)	141 (32.6)	75 (24.5)	0.02
Diabetes	121 (16.4)	72 (16.7)	49 (16.1)	NS
Alcohol abuse	129 (17.8)	49 (11.5)	80 (26.6)	<0.001
Psychiatric disorder	177 (24.1)	75 (17.5)	102 (33.6)	<0.001
Cancer	78 (10.6)	49 (11.3)	29 (9.5)	NS
Deceased during the followup	114 (15.3)	52 (12.2)	62 (20.7)	0.002

¹Early and late quitters combined.